Press releases

Featured
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services
NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services
NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association
NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting
NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis
NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer
NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer
NMD Pharma expands its US presence
NMD Pharma expands its US presence
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth
NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth
NMD Pharma Receives Grant from The Innovation Fund Denmark</a>
NMD Pharma Receives Grant from The Innovation Fund Denmark
NMD Pharma Initiates Combined Phase I/II Clinical trial
NMD Pharma Initiates Combined Phase I/II Clinical trial